JAKAVI has a well-characterised safety profile
Number of patients shown for the Phase III trial includes patients receiving either JAKAVI or BAT.
One enrolled patient in this trial was not included in the safety analysis.
- The safety profile of JAKAVI has been well established through clinical use in myelofibrosis as well as in PV1
The estimated cumulative patient exposure to JAKAVI is more than 14,000 patient treatment years1